Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences record dates, bonuses and splits
21 filed, newest first.
May 2026
19 May · Corporate action
May 2025
20 May · Corporate action
May 2024
17 May · Corporate action
Feb 2024
9 Feb · Corporate action
May 2023
18 May · Corporate action
May 2022
20 May · Corporate action
20 May · Corporate action
May 2021
Jun 2020
Mar 2020
11 Mar · Corporate action
Jul 2018
May 2018
Feb 2017
Mar 2016
Sep 2015
Aug 2015
May 2013
30 May · Corporate action
Company has fixed Record Date as June 12, 2013 for the purpose of determination of members entitled for dividend.
Apr 2010
12 Apr · Corporate action
The Bonus Committee of the Board of Directors at its meeting held to-day i.e. 9th April, 2010 made allotment of 6,82,49,507 equity shares of Rs.5/- each fully paid-up as Bonus Shares in the ratio 1 (One) new Bonus Equity Shares for every 2 (Two) Equity Shares to the members holding physical shares as on the 'Record Date' i.e. 6th April, 2010 and to the members holding shares in electronic form as per the details of beneficiaries furnished by NSDL/CDSL for the purpose, in accordance with the approval of the members at the Extra Ordinary General Meeting held on 22nd March 2010
Mar 2010
22 Mar · Corporate action
Committee of Board of Directors of the Company at its meeting held on March 22, 2010 has fixed April 06, 2010 as Record Date for the purpose of determining the members entitles to Bonus equity shares as recommended by the Board and approved by the shareholders in proportion of one new equity share of Rs.5/- each fully paid-up for every two equity shares of Rs.5/- each fully paid-up held by them.
Feb 2010
25 Feb · Corporate action
Board of Directors of the Company at their meeting held on February 25, 2010 have taken the following decisions. (1) To increase the authorised share Capital from existing Rs.700/- Millions to Rs.1100/- Millions and; (2) To issue bonus equity shares in the ratio of One equity share of Rs.5/- each fully paid-up for every Two equity shares of Rs.5/- each held by the shareholders of the Company on the Record Date to be fixed by the Board of Directors/Committee of the Board, subject to the approval of the shareholders and; (3) To convene Extra Ordinary General Meeting of Shareholders on March 22, 2010 for the purpose.
Dec 2008
5 Dec · Corporate action
Cadila Healthcare Limited had informed the Exchange that the Hon'ble High Court of Gujarat at Ahmedabad, has approved the Composite Scheme of Arrangement between Cadila Healthcare Limited ("Cadila") and Carnation Nutra - Analogue Foods Limited "(Carnation)" and Zydus Hospitals and Medical Research Private Limited ("ZHMRPL") on October 23, 2008. At the meeting of the committee of Board of Directors held on December 05, 2008 fixed January 05, 2009 as the Record date for the purpose of the determination of members entitled to receive the Shares of Carnation Nutra- Analogue Foods Limited in the ratio of 4(four) equity shares of Rs.10/- each fully paid up for every 15(Fifteen) equity shares of Rs. 5 each fully paid-up held by them on the record date as consideration for Demerger of Consumer Products Division (CPD) of the Company into Carnation. A detailed note on the shcme shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.